Literature DB >> 33172872

Necrotising enterocolitis in newborns receiving diazoxide.

Laura A Prado1, Marina Castro2,3, Dany E Weisz2,3, Amish Jain2,4, Jaques Belik2,5.   

Abstract

BACKGROUND: Frequent and severe gastrointestinal disturbances have been reported with the use of diazoxide in adults and older children. However, no studies have investigated the incidence of necrotising enterocolitis (NEC) in diazoxide-exposed newborns.
OBJECTIVE: To evaluate a possible association between diazoxide treatment for neonatal hypoglycaemia and the occurrence of NEC.
DESIGN: Multicentre retrospective cohort study.
SETTING: Three tertiary neonatal intensive care units in Toronto, Canada. PATIENTS: All patients treated with diazoxide for persistent hypoglycaemia between July 2012 and June 2017 were included. Overall incidence of NEC during those years on the participating units was obtained for comparison from the Canadian Neonatal Network database. MAIN OUTCOME: Incidence of NEC after diazoxide exposure.
RESULTS: Fifty-five neonates were exposed to diazoxide during the study period. Eighteen patients (33%) showed signs of feeding intolerance, and 7 developed NEC (13%). A diagnosis of NEC was more prevalent in the diazoxide-exposed, as compared with non-exposed infants of similar gestational age (OR 5.07, 95% CI 2.27 to 11.27; p<0.001), and greatest among infants born at 33-36 weeks' gestation (OR 13.76, 95% CI 3.77 to 50.23; p<0.001). All but one of the neonates diagnosed with NEC developed the disease within 7 days from initiation of diazoxide treatment.
CONCLUSION: The present data suggest a possible association between diazoxide exposure and the development of NEC in neonates. Further evaluation of the diazoxide-associated risk of NEC in neonates treated for persistent hypoglycaemia is warranted. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  intensive care; neonatology; pharmacology

Year:  2020        PMID: 33172872     DOI: 10.1136/archdischild-2020-319057

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  2 in total

1.  Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: Neonatal Glucose Care Optimisation (NeoGluCO) study - a randomised controlled trial.

Authors:  Don Laing; Eamon Walsh; Jane M Alsweiler; Sara M Hanning; Michael P Meyer; Julena Ardern; Wayne S Cutfield; Jenny Rogers; Greg D Gamble; J Geoffrey Chase; Jane E Harding; Christopher Jd McKinlay
Journal:  BMJ Open       Date:  2022-08-17       Impact factor: 3.006

2.  The danger of diazoxide in the neonatal intensive care unit.

Authors:  Jay Desai; Logan Key; Alyson Swindall; Kan Gaston; Ajay J Talati
Journal:  Ther Adv Drug Saf       Date:  2021-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.